The Impact of Social Factors on the Duration of Hospitalization for Tuberculosis
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Evaluation
2.3. Definitions of Terminology
2.4. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
TB | Tuberculosis |
INH | Isoniazid |
RFP | Rifampicin |
References
- Global Tuberculosis 2023 Report. Available online: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023 (accessed on 5 July 2024).
- Schaaf, H.S.; Collins, A.; Bekker, A.; Davies, P.D. Tuberculosis at extremes of age. Respirology 2010, 15, 747–763. [Google Scholar] [CrossRef] [PubMed]
- United Nations Department of Economic and Social Affairs, Population Division. World Population Ageing 2023; United Nations: New York, NY, USA, 2024. [Google Scholar]
- The Global Health Observatory. Life Expectancy at Birth (Years). 2023. Available online: https://www.who.int/data/gho/data/indicators/indicator-details/GHO/life-expectancy-at-birth-(years) (accessed on 5 June 2024).
- Teo, A.K.J.; Rahevar, K.; Morishita, F.; Ang, A.; Yoshiyama, T.; Ohkado, A.; Kawatsu, L.; Yamada, N.; Uchimura, K.; Choi, Y.; et al. Tuberculosis in older adults: Case studies from four countries with rapidly ageing populations in the western pacific region. BMC Public Health 2023, 23, 370. [Google Scholar] [CrossRef] [PubMed]
- World Bank. Life Expectancy at Birth, Total (Years)—Japan. Available online: https://data.worldbank.org/indicator/SP.DYN.LE00.IN?end=2022&locations=JP&skipRedirection=true&start=2022&view=bar (accessed on 6 June 2024).
- World Bank. Population Ages 65 and Above (% of Total Population). Available online: https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS (accessed on 5 July 2024).
- National Institute of Population and Social Security Research. Population Projections for Japan (2021–2070). Available online: https://www.ipss.go.jp/pp-zenkoku/e/zenkoku_e2023/pp_zenkoku2023e.asp (accessed on 5 July 2024).
- Tuberculosis in Japan. Annual Report 2022. Available online: https://jata-ekigaku.jp/wp-content/uploads/2022/11/TB-in-Japan_2022.pdf (accessed on 5 July 2024).
- Reported Tuberculosis in the United States. 2021. Available online: https://www.cdc.gov/tb/statistics/reports/2021/default.htm (accessed on 5 July 2024).
- Mori, A. Nihon no Kekkakuryuukou to Taisaku no 100nen [100 Years of Tuberculosis Epidemic and Countermeasures in Japan]. J. Jpn. Soc. Intern. Med. 2002, 91, 129–132. [Google Scholar] [CrossRef]
- Ministry of Health, Labour and Welfare. Promoting DOTS (Directly Observed Treatment, Short-course) for Tuberculosis Patients. 2004. Available online: https://www.mhlw.go.jp/web/t_doc?dataId=00tb2786&dataType=1&pageNo=1 (accessed on 13 August 2025).
- Ministry of Health, Labour and Welfare. Handling of Hospital Admission and Discharge and Work Restrictions for Tuberculosis Patients Under the Act on Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases. 2014. Available online: https://www.japaneselawtranslation.go.jp/en/laws/view/2830/en (accessed on 13 August 2025).
- Jindani, A.; Aber, V.R.; Edwards, E.A.; Mitchison, D.A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 1980, 121, 939–949. Available online: https://www.atsjournals.org/doi/10.1164/arrd.1980.121.6.939 (accessed on 13 August 2025). [PubMed]
- Ministry of Health, Labour and Welfare. Summary of Static/Dynamic Surveys of Medical Institutions and Hospital Report 2022; Health Statistics Office, Director-General for Statistics, Information Policy and Industrial Relations: Tokyo, Japan, 2022.
- Fujino, T.; Fusegawa, H.; Nishiumi, M.; Okubo, Y.; Kakizaki, T.; Maejima, K.; Sugimori, H. Epidemiological Study on Factors Affecting the Hospitalization Period of Patients with Active Tuberculosis. Kekkaku 2008, 83, 567–572. [Google Scholar] [CrossRef] [PubMed]
- Kato, S. Prospects of the Medical Care System for tuberculosis in Japan. Kekkaku 2019, 94, 527–533. Available online: https://www.kekkaku.gr.jp/pub/vol94%282019%29/vol94no11-12p527-533.pdf (accessed on 13 August 2025).
- Ministry of Health, Labour and Welfare. Nursing Care Employment Management Improvement Plan. 2021. Available online: https://www.mhlw.go.jp/content/11602000/000760549.pdf (accessed on 13 August 2025).
- Wada, A.; Kabayama, M.; Mukai, S.; Takabuchi, S.; Kato, H.; Nishizumi, T.; Kamide, K.; Tanikake, C. Anxiety-related factors among elder-care facility employees regarding adiission of tuberculosis patients after intatient-treatment completion. Jpn. J. Public Health 2022, 69, 931–938. [Google Scholar] [CrossRef]
- Sasaki, Y.; Yamagishi, F.; Yagi, T.; Hashimoto, T.; Bekku, R.; Kawasaki, T.; Shinozaki, A. Evaluation of Care for Elderly Pulmonary Tuberculosis Patients. Kekkaku 2007, 82, 733–739. [Google Scholar] [CrossRef] [PubMed]
- Ministry of Health, Labour and Welfare. Comprehensive Survey of Living Conditions 2022. Available online: https://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa22/index.html (accessed on 13 August 2025).
- Kaki, T.; Minakata, Y.; Sasaki, S.; Azuma, Y.; Kawabe, K.; Ono, H. Adverse Drug Reactions and Their Impact on the Treatment of Pulmonary Tuberculosis. J. Pulmonol. Res. Rep. 2021, 3, 1–4. [Google Scholar] [CrossRef]
- Nahid, P.; Dorman, S.E.; Alipanah, N.; Barry, P.M.; Brozek, J.L.; Cattamanchi, A.; Chaisson, L.H.; Chaisson, R.E.; Daley, C.L.; Grzemska, M.; et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin. Infect. Dis. 2016, 63, e147–e195. [Google Scholar] [CrossRef]
- Osei, F.A.; Enimil, A.; Ansong, D.; Laryea, D.O.; Mensah, N.K.; Amuzu, E.X.; Agyemang, E.O.; Sarpong, P.O.; Nyanor, I.; Dekugmen Yar, D. Review of Organism Density and Bacteriologic Conversion of Sputum among Tuberculosis Patients. Int. Sch. Res. Notices 2017, 2017, 7052583. [Google Scholar] [CrossRef]
- Azarkar, Z.; Sharifzadeh, G.; Ebrahimzadeh, A.; Olumi, S. Time to Sputum Smear Conversion in Smear-Positive Pulmonary Tuberculosis Patients and Factors for Delayed Conversion. Iran. J. Med. Sci. 2016, 41, 44–47. [Google Scholar] [PubMed]
- Caetano Mota, P.; Carvalho, A.; Valente, I.; Braga, R.; Duarte, R. Predictors of delayed sputum smear and culture conversion among a Portuguese population with pulmonary tuberculosis. Rev. Port. Pneumol. 2012, 18, 72–79. [Google Scholar] [CrossRef] [PubMed]
Characteristics | No. | |
---|---|---|
Age a (years) | 73.7 ± 20.0, 81 (69, 88) | |
Sex | Male/Female | 108/95 |
Nationality | Japan/Other countries | 197/6 |
Tuberculosis treatment history | Yes/No | 19/184 |
Diabetes | Yes/No | 31/172 |
Malignancy | Yes/No | 14/189 |
Use of corticosteroid or immunosuppressant | Yes/No | 11/192 |
Anorexia | Yes/No | 43/160 |
Albumin b (mg/dL) | 3.31 ± 0.82 | |
Lymphocyte count b (/μL) | 1077 ± 518 | |
Nursing level | A/B/C | 13/106/84 |
Daily Life Independence Level | Normal/J/A/B/C | 89/26/31/28/29 |
Drug sensitivity | no resistance/resistant to RFP/resistant to INH/other resistance/unidentified) | 158/0/19/0/17/9 |
Extrapulmonary Tuberculosis | Yes/No | 28/175 |
Cavitary lesion | Yes/No | 66/137 |
Sputum smear | ±/1+/2+/3+ | 23/39/78/63 |
Nucleic acid amplification method | positive/negative/not examined | 26/169/8 |
Treatment regimen | HR contained regimen/others | 171/32 |
Discontinuations Due to Adverse Effects | Yes/No | 49/154 |
Change in anti-tuberculous drugs | Yes/No | 47/156 |
Detection of non-tuberculous mycobacteria | Yes/No | 33/170 |
Duration until negative smear a (days) | 25.0 ± 18.4, 20 (14, 35.5) | |
Duration until negative culture a (days) | 44.1 ± 24.7, 42 (21, 61) | |
Residence before hospitalization | Hospital/Long-term care home/Home(alone)/Home (family of 2)/Home (family of ≥3) | 1/22/57/44/79 |
Discharge destination | Hospital/Long-term care home/Home(alone)/Home (family of 2)/Home (family of ≥3) | 49/16/39/37/62 |
Duration from release from isolation to discharge a (days) | 8.3 ± 12.6, 3 (1, 9) |
Correlation (vs. Duration of Hospitalization) | ||
---|---|---|
Correlation Coefficient | p Value | |
Age | 0.31 | <0.01 |
Sex | 0.02 | 0.82 |
Nationality | −0.10 | 0.18 |
Tuberculosis treatment history | 0.07 | 0.32 |
Diabetes | 0.31 | 0.51 |
Malignancy | 0.02 | 0.28 |
Use of corticosteroid or immunosuppressant | −0.10 | 0.48 |
Anorexia | 0.08 | 0.01 |
Albumin | 0.31 | <0.01 a |
Lymphocyte count | 0.02 | <0.01 |
Nursing necessity level | −0.10 | 0.04 |
Daily Life Independence Level | 0.09 | <0.01 |
Drug sensitivity | 0.31 | 0.81 |
Extrapulmonary tuberculosis | 0.02 | 0.49 |
Cavitary lesion | −0.10 | <0.01 |
Sputum smear | 0.10 | <0.01 |
Nucleic acid amplification method | 0.31 | 0.13 |
Treatment regimen | 0.02 | 0.01 |
Discontinuation due to adverse effects | −0.10 | <0.01 |
Change in anti-tuberculous drugs | 0.11 | <0.01 |
Detection of non-tuberculous mycobacteria | 0.02 | 0.05 |
Duration until negative smear | −0.10 | <0.01 |
Duration until negative culture | 0.12 | <0.01 |
Residence before hospitalization | 0.32 | 0.08 |
Discharge destination | 0.02 | <0.01 |
Duration from release form isolation to discharge | 0.47 | <0.001 |
Independent Variable | Regression Coefficient | Standardized Regression Coefficient (β) | Standard Error | t | p Value | VIF | 95% CI |
---|---|---|---|---|---|---|---|
intercept | 11.71 | 4.88 | 2.40 | 0.02 | |||
Duration until negative smear | 0.90 | 0.71 | 0.05 | 18.98 | <0.01 | 1.01 | [0.80, 0.99] |
Duration from release form isolation to discharge | 1.12 | 0.43 | 0.11 | 10.40 | <0.01 | 1.20 | [0.91, 0.99] |
Independence in daily life | 4.23 | 0.21 | 0.89 | 4.73 | <0.01 | 1.40 | [2.46, 6.00] |
Discharge destination | −1.87 | −0.10 | 0.88 | −2.12 | <0.05 | 1.45 | [−3.62, −0.13] |
R2 | 0.83 | ||||||
F | 4.50 | <0.05 |
Discharge Destination | Discharge Destination | Mean Difference | Standard Deviation | Significance Probability | 95% CI |
---|---|---|---|---|---|
Hospital | Long-term care home | 3.21 | 2.69 | 0.75 | [−4.19, 10.61] |
Home (alone) | 5.95 * | 2.00 | 0.03 | [0.44, 11.46] | |
Home (family of 2) | 9.36 ** | 2.03 | 0.00 | [3.76, 14.95] | |
Home (family of ≥3) | 9.01 ** | 1.78 | 0.00 | [4.10, 13.92] | |
Long-term care home | Home (alone) | 2.74 | 2.77 | 0.86 | [−4.89, 10.37] |
Home (family of 2) | 6.15 | 2.79 | 0.18 | [−1.54, 13.83] | |
Home (family of ≥3) | 5.80 | 2.62 | 0.18 | [−1.40, 13.00] | |
Home (alone) | Home (family of 2) | 3.41 | 2.14 | 0.50 | [−2.49, 9.30] |
Home (family of ≥3) | 3.06 | 1.91 | 0.50 | [−2.19, 8.31] | |
Home (family of ≥3) | −0.35 | 1.94 | 1.00 | [−5.68, 4.99] |
Independent Variable | Regression Coefficient | Standardized Regression Coefficient (β) | Standard Error | t | p Value | 95% CI |
---|---|---|---|---|---|---|
intercept | 9.20 | 5.97 | 1.54 | 0.13 | ||
Sputum smear | 9.06 | 0.35 | 2.00 | 4.52 | <0.001 | [5.09, 13.03] |
Cavitary lesion | 15.30 | 0.29 | 4.13 | 3.72 | <0.001 | [7.16, 23.50] |
TB treatment history | 17.59 | 0.20 | 6.70 | 2.62 | <0.05 | [4.31, 30.87] |
Treatment interruption due to adverse effect | 9.96 | 0.18 | 4.16 | 2.39 | <0.05 | [1.72, 18.20] |
R2 | 0.35 | |||||
F | 5.73 | <0.05 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ono, H.; Minakata, Y.; Kawabe, K.; Sasaki, S.; Murakami, Y.; Sonoda, T. The Impact of Social Factors on the Duration of Hospitalization for Tuberculosis. J. Clin. Med. 2025, 14, 5949. https://doi.org/10.3390/jcm14175949
Ono H, Minakata Y, Kawabe K, Sasaki S, Murakami Y, Sonoda T. The Impact of Social Factors on the Duration of Hospitalization for Tuberculosis. Journal of Clinical Medicine. 2025; 14(17):5949. https://doi.org/10.3390/jcm14175949
Chicago/Turabian StyleOno, Hideya, Yoshiaki Minakata, Kazumi Kawabe, Seigo Sasaki, Yusuke Murakami, and Takeru Sonoda. 2025. "The Impact of Social Factors on the Duration of Hospitalization for Tuberculosis" Journal of Clinical Medicine 14, no. 17: 5949. https://doi.org/10.3390/jcm14175949
APA StyleOno, H., Minakata, Y., Kawabe, K., Sasaki, S., Murakami, Y., & Sonoda, T. (2025). The Impact of Social Factors on the Duration of Hospitalization for Tuberculosis. Journal of Clinical Medicine, 14(17), 5949. https://doi.org/10.3390/jcm14175949